article

Screening In-Depth Focus 2019

Posted: 10 December 2019 | | No comments yet

In this In-Depth Focus are articles investigating how CROs can help to drive innovation and how CRISPR technologies could be used for drug screening purposes.

screening idf issue42019











To read this In-Depth Focus in full, please complete the form below. By clicking submit you confirm that you accept our terms and conditions and privacy policy.


*

*

*

*

*

*

*

*

This content is provided to you for free thanks to the kind support of our sponsor: BMG Labtech, ForteBio

Included in this in-depth focus: 

  • Open innovation – a collaboration between academia and the pharmaceutical industry to further leverage drug discovery expertise and assets
    Increasing numbers of companies in the pharma industry are consolidating their services and outsourcing to CROs to reduce business costs. AstraZeneca’s Marian Preston, David Murray and Mark Wigglesworth discuss how this can not only drive innovation but also prove successful in identifying lead compounds, as evidenced through recent collaborations.
  • CRISPR: kick-starting the revolution in drug discovery
    Gene editing using the CRISPR system has been established as the most powerful tool in the search for new drugs and is now being exploited for therapeutic purposes. Here, Pushpanathan Muthuirulan discusses the promises and wider opportunities of using CRISPR technology to open up the possibility of large-scale screening of drug targets. He also highlights the importance of implementing CRISPR technology into clinical practice for development of next-generation therapeutics and patient-tailored medicine.
Send this to a friend